Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.

"CONFLICTS OF INTEREST Thomas Horvatits is on the speakers’ bureau for Microgen diagnostics. Julian Schulze zur Wiesch is on the speakers‘ bureau for Gilead. Markus Cornberg advises and is on the speakers’ bureau for AbbVie, Gilead, and MSD. He advises AiCuris, GlaxoSmithKline, Jansen-Cilag, Novartis, Roche, and Swedish Orphan Biovitrum. He is on the speakers’ bureau for Falk. Heiner Wedemeyer consults, is on the speakers’ bureau, received grants, and has other interests with Gilead. He consults, received grants, and has other interests with Falk. He consults and has other interests with MSD. He consults and advises Roche. He consults and is on the speakers’ bureau for Pfizer. He is on the speakers’ bureau for the Falk Foundation. The remaining authors have no conflicts to report."

"FUNDING INFORMATION Daniel Todt was supported by grants from the German Ministry of Education and Research (BMBF, project VirBio; 01KI2106). Eike Steinmann was supported by grants from the German Federal Ministry of Health (ZMVI1-2518FSB705), the German Research Foundation (DFG, grant number: 398066876-GRK 2485/1), and the German Ministry of Education and Research (BMBF, project SILVIR: 16GW0202). Markus Cornberg, Heiner Wedemeyer, Patrick Behrendt, and Eike Steinmann were funded by a grant from the German Centre for Infection Research (DZIF). Heiner Wedemeyer and Eike Steinmann were funded by the German Ministry of Education and Research (HepEDiaSeq. 01EK2106A/B). All authors had access to the study data, and reviewed and approved the final manuscript."